SOLANA BEACH, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases ...

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025Gimoti remains only approved drug shown to ...

The stock has a fifty day moving average of $4.95 and a 200 day moving average of $5.30. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $14.16. A hedge fund recently bought a new ...

Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on ...